Corautus To Pursue Future Studies Of VEGF-2 Angina Therapy Following Lift Of Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm asserts adverse events in the Phase IIb GENASIS of patients with severe angina were not caused by the gene therapy.